Five Key Studies at the San Antonio Breast Cancer Symposium 2019 Conference

Check the Pharmacy Times® website for more information and be sure to watch for daily newsletters, online conference articles and videos, and social media updates.

Pharmacy Times® will be onsite during the 2019 San Antonio Breast Cancer Symposium, giving you live coverage and updates in the latest breast cancer treatment advances. The San Antonio Breast Cancer Symposium will run from December 10 through 14, 2019, and will be held at the Henry B. Gonzalez Convention Center in San Antonio, TX.

Check back on the Pharmacy Times® website for more information and be sure to watch for daily newsletters, online conference articles and videos, and social media updates.

Here are the top 5 studies to look out for:

5. Frontiers in HER2 Positive Breast Cancer

Experts from the Memorial Sloan Kettering Cancer Center will provide an overview of promising novel therapies, both proven and in development, for the treatment of refractory human epidermal growth factor receptor 2 (HER2) positive breast cancer. This will include a review of antibody drug conjugates, tyrosine kinase inhibitors, immune strategies, and future combination therapies.

4. Interferon-Response Gene Signatures Associated with De Novo and Acquired Resistance to CDK4/6 Inhibitors in ER+ Breast Cancer

The cyclin-dependent kinase (CDK) 4/6 inhibitors palbociclib, ribociclib, and abemaciclib have previously improved the outcome of patients with metastatic estrogen receptor (ER)-positive/HER2-negative breast cancer and are not under clinical investigation in early-stage breast cancer. Despite high efficacy, de novo and acquired resistance to CDK4/6i is common, therefore researchers wanted to determine the resistance to CDK4/6i in both ER-positive/HER2-negative breast cancer cell lines.

3. Immunotherapy in Breast Cancer: Enhancing Response to Checkpoint Balance

There is significant enthusiasm for immunotherapy to treat breast cancer patients; however, only a minority of patients respond to such therapy. Therefore, experts at the Dana-Farber Cancer Institute wanted to study how PARP inhibition might further modify a tumor microenvironment and how HR-positive tumors hide from immune recognition.

2. Targeting the Cell Cycle: Beyond CDK4/6 Inhibition

Multiple pre-clinical studies and some clinical data have provided insights to the mechanisms of resistance to CDK4/6 inhibitors guiding the development of clinical trials after progression on a CDK4/6 inhibitor. In this presentation, an expert from the Dana-Farber Cancer Institute will review the mechanisms of resistance to CDK4/6 inhibitors and the ongoing clinical trials investigating novel therapeutic strategies to enhance responses to CDK4/6 inhibitors and for treatment after the acquisition of resistance to CDK4/6 inhibitors.

1. Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases

Experts from the MD Anderson Cancer Center will describe the efficacy and safety of tucatinib, trastuzumab, and capecitabine, a treatment regimen under investigation for patients with advanced HER2-positive metastatic breast cancer refractory to standard-of-care regimens.